Literature DB >> 15176679

Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients.

K Decaestecker1, E Decaestecker, C Castellani, M Jaspers, H Cuppens, K De Boeck.   

Abstract

In this European study, the phenotype in 68 patients, homozygous or compound heterozygous for the G85E mutation, was investigated. Each index case was compared with two cystic fibrosis (CF) patients from the same clinic, matched for age and sex: one with pancreatic sufficiency (PS) and one with pancreatic insufficiency (PI). When comparing 31 G85E/F508del and F508del/F508del patients, there were no differences in median age at diagnosis, mean sweat chloride value, most recent weight for height, most recent forced expiratory volume in one second % predicted, prevalence of chronic Pseudomonas aeruginosa colonisation and typical CF complications. However, PI was less frequent in the G85E/F508del group. Comparison of 55 G85E patients (with second mutation known and not classified as mild) with PS controls (n=44) showed that the G85E patients had a significantly higher sweat chloride, more often failure to thrive at diagnosis, higher prevalence of PI, worse current weight for height, higher prevalence of chronic P. aeruginosa colonisation and liver cirrhosis. Pulse-chase experiments revealed that G85E cystic fibrosis transmembrane conductance regulator failed to mature on a M470 as well as on a V470 background. Therefore, G85E is a class II mutation. Although there is variability in its clinical presentation, G85E mutation results in a severe phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176679     DOI: 10.1183/09031936.04.00014804

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

1.  A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Authors:  Darren M Hutt; Salvatore Loguercio; Alexandre Rosa Campos; William E Balch
Journal:  J Mol Biol       Date:  2018-06-18       Impact factor: 5.469

2.  Ubiquitination of disease-causing CFTR variants in a microsome-based assay.

Authors:  Samuel K Estabrooks; Jeffrey L Brodsky
Journal:  Anal Biochem       Date:  2020-07-01       Impact factor: 3.365

3.  HDAC inhibitors rescue multiple disease-causing CFTR variants.

Authors:  Frédéric Anglès; Darren M Hutt; William E Balch
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

4.  Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening.

Authors:  Marco Cipolli; Carlo Castellani; Bridget Wilcken; John Massie; Karen McKay; Margie Gruca; Anna Tamanini; Maurice Baroukh Assael; Kevin Gaskin
Journal:  Arch Dis Child       Date:  2007-04-20       Impact factor: 3.791

5.  Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation.

Authors:  Sofía C Ortiz; Santiago J Aguirre; Sofía Flores; Claudio Maldonado; Juan Mejía; Lilian Salinas
Journal:  Mol Genet Genomic Med       Date:  2017-10-11       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.